PMX 53
Alternative Names: Hydrocinnamate analogues - Promics; PMX53Latest Information Update: 09 Mar 2011
Price :
$50 *
At a glance
- Originator Peptech; The University of Queensland
- Developer Arana Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Peptides
- Mechanism of Action Complement C5a inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoarthritis
- Discontinued Age-related macular degeneration; Burns; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 09 Mar 2011 No development reported - Preclinical for Osteoarthritis in Australia (PO)
- 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
- 19 Feb 2009 Discontinued - Phase-I for Age-related macular degeneration in Australia (PO)